BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Badley AD, Sainski A, Wightman F, Lewin SR. Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis 2013;4:e718. [PMID: 23846220 DOI: 10.1038/cddis.2013.248] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Cunyat F, Rainho JN, West B, Swainson L, McCune JM, Stevenson M. Colony-Stimulating Factor 1 Receptor Antagonists Sensitize Human Immunodeficiency Virus Type 1-Infected Macrophages to TRAIL-Mediated Killing. J Virol 2016;90:6255-62. [PMID: 27122585 DOI: 10.1128/JVI.00231-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
2 Cummins NW, Sainski AM, Dai H, Natesampillai S, Pang YP, Bren GD, de Araujo Correia MCM, Sampath R, Rizza SA, O'Brien D, Yao JD, Kaufmann SH, Badley AD. Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. J Virol 2016;90:4032-48. [PMID: 26842479 DOI: 10.1128/JVI.03179-15] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
3 Hattori SI, Matsuda K, Tsuchiya K, Gatanaga H, Oka S, Yoshimura K, Mitsuya H, Maeda K. Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro. Front Microbiol 2018;9:2022. [PMID: 30283406 DOI: 10.3389/fmicb.2018.02022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
4 Mohammadi P, di Iulio J, Muñoz M, Martinez R, Bartha I, Cavassini M, Thorball C, Fellay J, Beerenwinkel N, Ciuffi A, Telenti A. Dynamics of HIV latency and reactivation in a primary CD4+ T cell model. PLoS Pathog 2014;10:e1004156. [PMID: 24875931 DOI: 10.1371/journal.ppat.1004156] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
5 Kruize Z, Kootstra NA. The Role of Macrophages in HIV-1 Persistence and Pathogenesis. Front Microbiol 2019;10:2828. [PMID: 31866988 DOI: 10.3389/fmicb.2019.02828] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
6 Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the Inhibition of Viral Infections. Molecules 2015;20:14051-81. [PMID: 26247927 DOI: 10.3390/molecules200814051] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
7 Dou X, Chen L, Lei M, Zellmer L, Jia Q, Ling P, He Y, Yang W, Liao DJ. Evaluating the Remote Control of Programmed Cell Death, with or without a Compensatory Cell Proliferation. Int J Biol Sci 2018;14:1800-12. [PMID: 30443184 DOI: 10.7150/ijbs.26962] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Kumar A, Herbein G. The macrophage: a therapeutic target in HIV-1 infection. Mol Cell Ther 2014;2:10. [PMID: 26056579 DOI: 10.1186/2052-8426-2-10] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
9 Cummins NW, Badley AD. Can HIV Be Cured and Should We Try? Mayo Clin Proc 2015;90:705-9. [PMID: 25944260 DOI: 10.1016/j.mayocp.2015.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Badley AD. "Much ado to achieve nothing: prospects for curing HIV infection". Mol Cell Ther 2014;2:9. [PMID: 26056578 DOI: 10.1186/2052-8426-2-9] [Reference Citation Analysis]
11 Matsuda K, Islam S, Takada T, Tsuchiya K, Yang Tan BJ, Hattori SI, Katsuya H, Kitagawa K, Kim KS, Matsuo M, Sugata K, Delino NS, Gatanaga H, Yoshimura K, Matsushita S, Mitsuya H, Iwami S, Satou Y, Maeda K. A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro. Cell Rep Methods 2021;1:100122. [PMID: 35475215 DOI: 10.1016/j.crmeth.2021.100122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Boliar S, Russell DG. Lnc(ing)RNAs to the "shock and kill" strategy for HIV-1 cure. Mol Ther Nucleic Acids 2021;23:1272-80. [PMID: 33717648 DOI: 10.1016/j.omtn.2021.02.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Kumar A, Abbas W, Herbein G. HIV-1 latency in monocytes/macrophages. Viruses 2014;6:1837-60. [PMID: 24759213 DOI: 10.3390/v6041837] [Cited by in Crossref: 132] [Cited by in F6Publishing: 123] [Article Influence: 16.5] [Reference Citation Analysis]
14 Mbita Z, Hull R, Dlamini Z. Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets. Viruses 2014;6:3181-227. [PMID: 25196285 DOI: 10.3390/v6083181] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
15 Boliar S, Gludish DW, Jambo KC, Kamng'ona R, Mvaya L, Mwandumba HC, Russell DG. Inhibition of the lncRNA SAF drives activation of apoptotic effector caspases in HIV-1-infected human macrophages. Proc Natl Acad Sci U S A 2019;116:7431-8. [PMID: 30918127 DOI: 10.1073/pnas.1818662116] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
16 Telwatte S, Morón-López S, Aran D, Kim P, Hsieh C, Joshi S, Montano M, Greene WC, Butte AJ, Wong JK, Yukl SA. Heterogeneity in HIV and cellular transcription profiles in cell line models of latent and productive infection: implications for HIV latency. Retrovirology 2019;16:32. [PMID: 31711503 DOI: 10.1186/s12977-019-0494-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
17 Jean MJ, Fiches G, Hayashi T, Zhu J. Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors. AIDS Res Hum Retroviruses 2019;35:1-24. [PMID: 30351168 DOI: 10.1089/AID.2018.0153] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
18 Polizzotto MN, Chen G, Tressler RL, Godfrey C. Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions. Drugs 2015;75:1447-59. [PMID: 26224205 DOI: 10.1007/s40265-015-0426-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
19 Gaebler C, Nogueira L, Stoffel E, Oliveira TY, Breton G, Millard KG, Turroja M, Butler A, Ramos V, Seaman MS, Reeves JD, Petroupoulos CJ, Shimeliovich I, Gazumyan A, Jiang CS, Jilg N, Scheid JF, Gandhi R, Walker BD, Sneller MC, Fauci A, Chun TW, Caskey M, Nussenzweig MC. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 2022. [PMID: 35418681 DOI: 10.1038/s41586-022-04597-1] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014;10:e1004071. [PMID: 24722454 DOI: 10.1371/journal.ppat.1004071] [Cited by in Crossref: 191] [Cited by in F6Publishing: 185] [Article Influence: 23.9] [Reference Citation Analysis]
21 De Crignis E, Mahmoudi T. The Multifaceted Contributions of Chromatin to HIV-1 Integration, Transcription, and Latency. Int Rev Cell Mol Biol 2017;328:197-252. [PMID: 28069134 DOI: 10.1016/bs.ircmb.2016.08.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
22 Diaz RS, Shytaj IL, Giron LB, Obermaier B, Della Libera E Jr, Galinskas J, Dias D, Hunter J, Janini M, Gosuen G, Ferreira PA, Sucupira MC, Maricato J, Fackler O, Lusic M, Savarino A; SPARC Working Group. Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial. Int J Antimicrob Agents 2019;54:592-600. [PMID: 31394172 DOI: 10.1016/j.ijantimicag.2019.08.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
23 Chirullo B, Sgarbanti R, Limongi D, Shytaj IL, Alvarez D, Das B, Boe A, DaFonseca S, Chomont N, Liotta L, Petricoin EI, Norelli S, Pelosi E, Garaci E, Savarino A, Palamara AT. A candidate anti-HIV reservoir compound, auranofin, exerts a selective 'anti-memory' effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis 2013;4:e944. [PMID: 24309931 DOI: 10.1038/cddis.2013.473] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
24 Trypsteen W, Mohammadi P, Van Hecke C, Mestdagh P, Lefever S, Saeys Y, De Bleser P, Vandesompele J, Ciuffi A, Vandekerckhove L, De Spiegelaere W. Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay. Sci Rep 2016;6:36111. [PMID: 27782208 DOI: 10.1038/srep36111] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
25 Margolis DM. How Might We Cure HIV? Curr Infect Dis Rep 2014;16:392. [PMID: 24562540 DOI: 10.1007/s11908-014-0392-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
26 Anderson EM, Maldarelli F. The role of integration and clonal expansion in HIV infection: live long and prosper. Retrovirology 2018;15:71. [PMID: 30352600 DOI: 10.1186/s12977-018-0448-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
27 Khan SZ, Hand N, Zeichner SL. Apoptosis-induced activation of HIV-1 in latently infected cell lines. Retrovirology 2015;12:42. [PMID: 25980942 DOI: 10.1186/s12977-015-0169-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
28 Brockman MA, Jones RB, Brumme ZL. Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. Front Immunol 2015;6:506. [PMID: 26483795 DOI: 10.3389/fimmu.2015.00506] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
29 Passos DF, Schetinger MRC, Leal DB. Purinergic signaling and human immunodeficiency virus/acquired immune deficiency syndrome: From viral entry to therapy. World J Virology 2015; 4(3): 285-294 [PMID: 26279989 DOI: 10.5501/wjv.v4.i3.285] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
30 Cummins NW, Badley AD. Making sense of how HIV kills infected CD4 T cells: implications for HIV cure. Mol Cell Ther 2014;2:20. [PMID: 26056587 DOI: 10.1186/2052-8426-2-20] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
31 Mikhailova A, Valle-Casuso JC, Sáez-Cirión A. Cellular Determinants of HIV Persistence on Antiretroviral Therapy. Adv Exp Med Biol 2018;1075:213-39. [PMID: 30030795 DOI: 10.1007/978-981-13-0484-2_9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
32 Castellano P, Prevedel L, Eugenin EA. HIV-infected macrophages and microglia that survive acute infection become viral reservoirs by a mechanism involving Bim. Sci Rep 2017;7:12866. [PMID: 28993666 DOI: 10.1038/s41598-017-12758-w] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
33 Daussy CF, Galais M, Pradel B, Robert-Hebmann V, Sagnier S, Pattingre S, Biard-Piechaczyk M, Espert L. HIV-1 Env induces pexophagy and an oxidative stress leading to uninfected CD4+ T cell death. Autophagy 2021;17:2465-74. [PMID: 33073673 DOI: 10.1080/15548627.2020.1831814] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Rasmussen TA, Tolstrup M, Søgaard OS. Reversal of Latency as Part of a Cure for HIV-1. Trends Microbiol 2016;24:90-7. [PMID: 26690612 DOI: 10.1016/j.tim.2015.11.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 9.4] [Reference Citation Analysis]
35 Hori T, Barnor J, Nguyen Huu T, Morinaga O, Hamano A, Ndzinu J, Frimpong A, Minta-Asare K, Amoa-Bosompem M, Brandful J, Odoom J, Bonney J, Tuffour I, Owusu BA, Ofosuhene M, Atchoglo P, Sakyiamah M, Adegle R, Appiah-Opong R, Ampofo W, Koram K, Nyarko A, Okine L, Edoh D, Appiah A, Uto T, Yoshinaka Y, Uota S, Shoyama Y, Yamaoka S. Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus. Biochem Biophys Res Commun 2015;459:288-93. [PMID: 25727021 DOI: 10.1016/j.bbrc.2015.02.102] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
36 Sebastian NT, Collins KL. Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Rev Anti Infect Ther 2014;12:1187-201. [PMID: 25189526 DOI: 10.1586/14787210.2014.956094] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
37 Petravic J, Rasmussen TA, Lewin SR, Kent SJ, Davenport MP. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. J Virol 2017;91:e02092-16. [PMID: 28202759 DOI: 10.1128/JVI.02092-16] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
38 Ivanov AV, Valuev-Elliston VT, Ivanova ON, Kochetkov SN, Starodubova ES, Bartosch B, Isaguliants MG. Oxidative Stress during HIV Infection: Mechanisms and Consequences. Oxid Med Cell Longev 2016;2016:8910396. [PMID: 27829986 DOI: 10.1155/2016/8910396] [Cited by in Crossref: 130] [Cited by in F6Publishing: 133] [Article Influence: 21.7] [Reference Citation Analysis]
39 Csősz É, Tóth F, Mahdi M, Tsaprailis G, Emri M, Tőzsér J. Analysis of networks of host proteins in the early time points following HIV transduction. BMC Bioinformatics 2019;20:398. [PMID: 31315557 DOI: 10.1186/s12859-019-2990-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
40 Timilsina U, Gaur R. Modulation of apoptosis and viral latency - an axis to be well understood for successful cure of human immunodeficiency virus. J Gen Virol 2016;97:813-24. [PMID: 26764023 DOI: 10.1099/jgv.0.000402] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
41 Paim AC, Badley AD, Cummins NW. Mechanisms of Human Immunodeficiency Virus-Associated Lymphocyte Regulated Cell Death. AIDS Res Hum Retroviruses 2020;36:101-15. [PMID: 31659912 DOI: 10.1089/AID.2019.0213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
42 Li BX, Zhang H, Liu Y, Li Y, Zheng JJ, Li WX, Feng K, Sun M, Dai SX. Novel pathways of HIV latency reactivation revealed by integrated analysis of transcriptome and target profile of bryostatin. Sci Rep 2020;10:3511. [PMID: 32103135 DOI: 10.1038/s41598-020-60614-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
43 Maldarelli F. The role of HIV integration in viral persistence: no more whistling past the proviral graveyard. J Clin Invest 2016;126:438-47. [PMID: 26829624 DOI: 10.1172/JCI80564] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
44 Cummins NW, Sainski-Nguyen AM, Natesampillai S, Aboulnasr F, Kaufmann S, Badley AD. Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition. J Virol 2017;91:e00012-17. [PMID: 28331083 DOI: 10.1128/JVI.00012-17] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
45 Kuo HH, Ahmad R, Lee GQ, Gao C, Chen HR, Ouyang Z, Szucs MJ, Kim D, Tsibris A, Chun TW, Battivelli E, Verdin E, Rosenberg ES, Carr SA, Yu XG, Lichterfeld M. Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells. Immunity 2018;48:1183-1194.e5. [PMID: 29802019 DOI: 10.1016/j.immuni.2018.04.004] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 15.0] [Reference Citation Analysis]
46 Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, Greene WC, Wong JK. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Nat Med 2016;22:807-11. [PMID: 27294875 DOI: 10.1038/nm.4124] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
47 Jean MJ, Hayashi T, Huang H, Brennan J, Simpson S, Purmal A, Gurova K, Keefer MC, Kobie JJ, Santoso NG, Zhu J. Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation. Front Microbiol 2017;8:2007. [PMID: 29089933 DOI: 10.3389/fmicb.2017.02007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
48 Borrajo A, Ranazzi A, Pollicita M, Bellocchi MC, Salpini R, Mauro MV, Ceccherini-Silberstein F, Perno CF, Svicher V, Aquaro S. Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage. Medicina (Kaunas) 2019;55:E297. [PMID: 31234437 DOI: 10.3390/medicina55060297] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
49 Milovanovic M, Arsenijevic A, Milovanovic J, Kanjevac T, Arsenijevic N. Nanoparticles in Antiviral Therapy. Antimicrobial Nanoarchitectonics. Elsevier; 2017. pp. 383-410. [DOI: 10.1016/b978-0-323-52733-0.00014-8] [Cited by in Crossref: 28] [Article Influence: 5.6] [Reference Citation Analysis]
50 Benso B, Rosalen PL, Pasetto S, Marquezin MCS, Freitas-Blanco V, Murata RM. Malva sylvestris derivatives as inhibitors of HIV-1 BaL infection. Nat Prod Res 2021;35:1064-9. [PMID: 31429300 DOI: 10.1080/14786419.2019.1619720] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
51 Rasmussen TA, Lewin SR. Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents? Curr Opin HIV AIDS 2016;11:394-401. [PMID: 26974532 DOI: 10.1097/COH.0000000000000279] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 18.4] [Reference Citation Analysis]